Literature DB >> 29544603

The Diagnostic Yield of Brugada Syndrome After Sudden Death With Normal Autopsy.

Michael Papadakis1, Efstathios Papatheodorou1, Greg Mellor1, Hariharan Raju1, Rachel Bastiaenen2, Yanushi Wijeyeratne2, Sara Wasim2, Bode Ensam1, Gherardo Finocchiaro1, Belinda Gray2, Aneil Malhotra1, Andrew D'Silva1, Nina Edwards2, Della Cole2, Virginia Attard2, Velislav N Batchvarov2, Maria Tome-Esteban2, Tessa Homfray2, Mary N Sheppard2, Sanjay Sharma3, Elijah R Behr2.   

Abstract

BACKGROUND: Familial evaluation after a sudden death with negative autopsy (sudden arrhythmic death syndrome; SADS) may identify relatives at risk of fatal arrhythmias.
OBJECTIVES: This study aimed to assess the impact of systematic ajmaline provocation testing using high right precordial leads (RPLs) on the diagnostic yield of Brugada syndrome (BrS) in a large cohort of SADS families.
METHODS: Three hundred three SADS families (911 relatives) underwent evaluation with resting electrocardiogram using conventional and high RPLs, echocardiography, exercise, and 24-h electrocardiogram monitor. An ajmaline test with conventional and high RPLs was undertaken in 670 (74%) relatives without a familial diagnosis after initial evaluation. Further investigations were guided by clinical suspicion.
RESULTS: An inherited cardiac disease was diagnosed in 128 (42%) families and 201 (22%) relatives. BrS was the most prevalent diagnosis (n = 85, 28% of families; n = 140, 15% of relatives). Ajmaline testing was required to unmask the BrS in 97% of diagnosed individuals. The use of high RPLs showed a 16% incremental diagnostic yield of ajmaline testing by diagnosing BrS in an additional 49 families. There were no differences of the characteristics between individuals and families with a diagnostic pattern in the conventional and the high RPLs. On follow-up, a spontaneous type 1 Brugada pattern and/or clinically significant arrhythmic events developed in 17% (n = 25) of the concealed BrS cohort.
CONCLUSIONS: Systematic use of ajmaline testing with high RPLs increases substantially the yield of BrS in SADS families. Assessment should be performed in expert centers where patients are counseled appropriately for the potential implications of provocation testing.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ajmaline provocation testing; cardiomyopathy; ion channelopathy; sudden arrhythmic death syndrome

Mesh:

Substances:

Year:  2018        PMID: 29544603     DOI: 10.1016/j.jacc.2018.01.031

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

Review 1.  [Genetic testing to prevent sudden cardiac death].

Authors:  B Stallmeyer; S Dittmann; E Schulze-Bahr
Journal:  Internist (Berl)       Date:  2018-08       Impact factor: 0.743

2.  Diagnostic yield of hypertrophic cardiomyopathy in first-degree relatives of decedents with idiopathic left ventricular hypertrophy.

Authors:  Gherardo Finocchiaro; Harshil Dhutia; Belinda Gray; Bode Ensam; Stathis Papatheodorou; Chris Miles; Aneil Malhotra; Zeph Fanton; Paulo Bulleros; Tessa Homfray; Adam A Witney; Nicholas Bunce; Lisa J Anderson; James S Ware; Rajan Sharma; Maite Tome; Elijah R Behr; Mary N Sheppard; Michael Papadakis; Sanjay Sharma
Journal:  Europace       Date:  2020-04-01       Impact factor: 5.214

3.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.

Authors:  Arthur A M Wilde; Christopher Semsarian; Manlio F Márquez; Alireza Sepehri Shamloo; Michael J Ackerman; Euan A Ashley; Back Sternick Eduardo; Héctor Barajas-Martinez; Elijah R Behr; Connie R Bezzina; Jeroen Breckpot; Philippe Charron; Priya Chockalingam; Lia Crotti; Michael H Gollob; Steven Lubitz; Naomasa Makita; Seiko Ohno; Martín Ortiz-Genga; Luciana Sacilotto; Eric Schulze-Bahr; Wataru Shimizu; Nona Sotoodehnia; Rafik Tadros; James S Ware; David S Winlaw; Elizabeth S Kaufman; Takeshi Aiba; Andreas Bollmann; Jong-Il Choi; Aarti Dalal; Francisco Darrieux; John Giudicessi; Mariana Guerchicoff; Kui Hong; Andrew D Krahn; Ciorsti Mac Intyre; Judith A Mackall; Lluís Mont; Carlo Napolitano; Pablo Ochoa Juan; Petr Peichl; Alexandre C Pereira; Peter J Schwartz; Jon Skinner; Christoph Stellbrink; Jacob Tfelt-Hansen; Thomas Deneke
Journal:  J Arrhythm       Date:  2022-05-31

4.  Two Faces of Brugada Syndrome.

Authors:  Piotr Kêdziora; Aleksandra Stasiak
Journal:  Indian Pediatr       Date:  2022-04-15       Impact factor: 3.839

5.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.

Authors:  Arthur A M Wilde; Christopher Semsarian; Manlio F Márquez; Alireza Sepehri Shamloo; Michael J Ackerman; Euan A Ashley; Eduardo Back Sternick; Héctor Barajas-Martinez; Elijah R Behr; Connie R Bezzina; Jeroen Breckpot; Philippe Charron; Priya Chockalingam; Lia Crotti; Michael H Gollob; Steven Lubitz; Naomasa Makita; Seiko Ohno; Martín Ortiz-Genga; Luciana Sacilotto; Eric Schulze-Bahr; Wataru Shimizu; Nona Sotoodehnia; Rafik Tadros; James S Ware; David S Winlaw; Elizabeth S Kaufman; Takeshi Aiba; Andreas Bollmann; Jong Il Choi; Aarti Dalal; Francisco Darrieux; John Giudicessi; Mariana Guerchicoff; Kui Hong; Andrew D Krahn; Ciorsti MacIntyre; Judith A Mackall; Lluís Mont; Carlo Napolitano; Juan Pablo Ochoa; Petr Peichl; Alexandre C Pereira; Peter J Schwartz; Jon Skinner; Christoph Stellbrink; Jacob Tfelt-Hansen; Thomas Deneke
Journal:  Europace       Date:  2022-09-01       Impact factor: 5.486

6.  Clinical Profile and Long-Term Follow-Up of Children with Brugada Syndrome.

Authors:  Ibrahim El-Battrawy; Gretje Roterberg; Kim Schlentrich; Volker Liebe; Siegfried Lang; Boris Rudic; Erol Tülümen; Xiaobo Zhou; Martin Borggrefe; Ibrahim Akin
Journal:  Pediatr Cardiol       Date:  2019-11-20       Impact factor: 1.655

7.  2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families.

Authors:  Martin K Stiles; Arthur A M Wilde; Dominic J Abrams; Michael J Ackerman; Christine M Albert; Elijah R Behr; Sumeet S Chugh; Martina C Cornel; Karen Gardner; Jodie Ingles; Cynthia A James; Jyh-Ming Jimmy Juang; Stefan Kääb; Elizabeth S Kaufman; Andrew D Krahn; Steven A Lubitz; Heather MacLeod; Carlos A Morillo; Koonlawee Nademanee; Vincent Probst; Elizabeth V Saarel; Luciana Sacilotto; Christopher Semsarian; Mary N Sheppard; Wataru Shimizu; Jonathan R Skinner; Jacob Tfelt-Hansen; Dao Wu Wang
Journal:  Heart Rhythm       Date:  2020-10-19       Impact factor: 6.343

8.  2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families.

Authors:  Martin K Stiles; Arthur A M Wilde; Dominic J Abrams; Michael J Ackerman; Christine M Albert; Elijah R Behr; Sumeet S Chugh; Martina C Cornel; Karen Gardner; Jodie Ingles; Cynthia A James; Jyh-Ming Jimmy Juang; Stefan Kääb; Elizabeth S Kaufman; Andrew D Krahn; Steven A Lubitz; Heather MacLeod; Carlos A Morillo; Koonlawee Nademanee; Vincent Probst; Elizabeth V Saarel; Luciana Sacilotto; Christopher Semsarian; Mary N Sheppard; Wataru Shimizu; Jonathan R Skinner; Jacob Tfelt-Hansen; Dao Wu Wang
Journal:  J Arrhythm       Date:  2021-04-08

Review 9.  Genetics and genomics of arrhythmic risk: current and future strategies to prevent sudden cardiac death.

Authors:  Chiara Scrocco; Connie R Bezzina; Michael J Ackerman; Elijah R Behr
Journal:  Nat Rev Cardiol       Date:  2021-05-24       Impact factor: 32.419

Review 10.  Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments.

Authors:  Nicoletta Orphanou; Efstathios Papatheodorou; Aris Anastasakis
Journal:  Heart Fail Rev       Date:  2021-07-14       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.